Cyclophosphamide

Generic Name: Cyclophosphamide

Brand Names: Procytox

Drug Type: Small Molecule

Chemical Formula: C_₇H_₁₅Cl_₂N_₂O_₂P

CAS Number: 50-18-0

Unique Ingredient Identifier: 6UXW23996M

Background: Precursor of an alkylating nitrogen mustard antineoplastic and immunosuppressive agent that must be activated in the liver to form the active aldophosphamide. It has been used in the treatment of lymphoma and leukemia. Its side effect, alopecia, has been used for defleecing sheep. Cyclophosphamide may also cause sterility, birth defects, mutations, and cancer.

Indication: Cyclophosphamide is indicated for the treatment of malignant lymphomas, multiple myeloma, leukemias, mycosis fungoides (advanced disease), neuroblastoma (disseminated disease), adenocarcinoma of the ovary, retinoblastoma, and carcinoma of the breast. It is also indicated for the treatment of biopsy-proven minimal change nephrotic syndrome in pediatric patients.

Associated Conditions: Acute Lymphoblastic Leukaemias (ALL), Acute Myeloid Leukemia, Acute monocytic leukemia, Adenocarcinoma of the Ovaries, Breast Cancer, Burkitt Lymphoma, Chronic Lymphocytic Leukemia, Chronic Myelogenous Leukemia (CML), Hodgkins Disease (HD), Lung Cancer, Lupus, Lymphocytic Lymphomas, Lymphoma, Multiple Myeloma (MM), Multiple Sclerosis, Nephrotic syndrome with lesion of minimal change glomerulonephritis, Non-Hodgkin's Lymphoma (NHL), Retinoblastoma, Advanced Alibert-Bazin syndrome, Chronic Granulocytic Leukemias, Disseminated Neuroblastoma (NB), Histiocytic lymphoma, Mixed-cell type lymphoma

Associated Therapies: -

Clinical Trials

Vaccine Therapy Compared With Interferon Alfa in Treating Patients With Stage III Melanoma

Phase 2

Terminated

Conditions: Melanoma (Skin)

First Posted Date: 2004-04-23

Last Posted Date: 2015-12-03

Lead Sponsor: AVAX Technologies

Target Recruit Count: 425

Registration Number: NCT00003715

Locations: 🇺🇸
Georgia Cancer Specialists, Decatur, Georgia, United States
🇺🇸
Yale Comprehensive Cancer Center, New Haven, Connecticut, United States
🇺🇸
Jersey Shore Cancer Center, Neptune, New Jersey, United States

and more 14 locations

Chemotherapy, Radiation Therapy, and Peripheral Stem Cell Transplantation in Treating Patients With Hematologic Cancer

Phase 1

Completed

Conditions: Leukemia
Lymphoma
Multiple Myeloma and Plasma Cell Neoplasm
Myelodysplastic Syndromes

Interventions: Drug: Cyclophosphamide
Drug: Psoralen
Drug: Thiotepa
Procedure: Allogeneic bone marrow transplantation
Procedure: In vitro-treated peripheral blood stem cell transplantation (PBSCT)
Radiation: Radiation Therapy (RT)

First Posted Date: 2004-04-23

Last Posted Date: 2018-10-26

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 7

Registration Number: NCT00005092

Locations: 🇺🇸
University of Illinois at Chicago, Chicago, Illinois, United States
🇺🇸
University of Texas - MD Anderson Cancer Center, Houston, Texas, United States
🇺🇸
Washington University Barnard Cancer Center, Saint Louis, Missouri, United States

Bone Marrow Transplantation in Treating Patients With Acute Leukemia in First or Second Remission

Phase 3

Completed

Conditions: Leukemia

First Posted Date: 2004-04-22

Last Posted Date: 2013-06-26

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Registration Number: NCT00002534

Locations: 🇺🇸
Memorial Sloan-Kettering Cancer Center, New York, New York, United States

S9623, Combination Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Women With Breast Cancer

Phase 3

Terminated

Conditions: Breast Cancer

Interventions: Biological: filgrastim
Drug: carboplatin
Drug: cyclophosphamide
Drug: carmustine
Drug: doxorubicin hydrochloride
Drug: cisplatin
Drug: tamoxifen citrate
Radiation: radiation therapy
Drug: paclitaxel
Drug: thiotepa
Procedure: autologous bone marrow transplantation
Procedure: peripheral blood stem cell transplantation

First Posted Date: 2004-04-22

Last Posted Date: 2013-01-24

Lead Sponsor: SWOG Cancer Research Network

Target Recruit Count: 602

Registration Number: NCT00002772

Locations: 🇺🇸
Memorial Sloan-Kettering Cancer Center, New York, New York, United States

Cyclophosphamide and Filgrastim in Treating Patients With Stage IV, Relapsed, or Refractory Low-Grade Follicular Non-Hodgkin's Lymphoma

Phase 2

Completed

Conditions: Lymphoma

Interventions: Biological: filgrastim
Drug: cyclophosphamide

First Posted Date: 2004-04-22

Last Posted Date: 2016-07-01

Lead Sponsor: Alliance for Clinical Trials in Oncology

Target Recruit Count: 29

Registration Number: NCT00002501

Locations: 🇺🇸
State University of New York - Upstate Medical University, Syracuse, New York, United States
🇺🇸
Marlene & Stewart Greenebaum Cancer Center, University of Maryland, Baltimore, Maryland, United States
🇺🇸
Ellis Fischel Cancer Center - Columbia, Columbia, Missouri, United States

and more 12 locations

Combination Chemotherapy and Radiation Therapy in Treating Children With Previously Untreated Stage II, Stage III, or Stage IV Hodgkin's Disease

Phase 2

Completed

Conditions: Lymphoma

Interventions: Biological: bleomycin sulfate
Biological: filgrastim
Drug: ABVD regimen
Drug: cyclophosphamide
Drug: dacarbazine
Drug: doxorubicin hydrochloride
Drug: etoposide
Drug: prednisone
Drug: procarbazine hydrochloride
Drug: vinblastine sulfate
Drug: vincristine sulfate
Radiation: radiation therapy

First Posted Date: 2004-04-15

Last Posted Date: 2014-02-26

Lead Sponsor: Children's Oncology Group

Target Recruit Count: 99

Registration Number: NCT00004010

Locations: 🇺🇸
CCOP - Merit Care Hospital, Fargo, North Dakota, United States
🇺🇸
Mayo Clinic Cancer Center, Rochester, Minnesota, United States
🇺🇸
University of Wisconsin Comprehensive Cancer Center, Madison, Wisconsin, United States

and more 37 locations

Monoclonal Antibody Therapy, Cyclophosphamide, and Total-Body Irradiation Followed by Peripheral Stem Cell Transplantation in Treating Patients With Advanced Recurrent Acute Lymphocytic Leukemia

Phase 2

Completed

Conditions: Leukemia

First Posted Date: 2004-04-14

Last Posted Date: 2010-04-02

Lead Sponsor: Fred Hutchinson Cancer Center

Target Recruit Count: 40

Registration Number: NCT00003870

Locations: 🇺🇸
University of Washington Medical Center, Seattle, Washington, United States
🇺🇸
Fred Hutchinson Cancer Research Center, Seattle, Washington, United States

High Dose Chemotherapy Plus Peripheral Stem Cell Transplantation Compared With Standard Therapy in Treating Women With Metastatic or Recurrent Breast Cancer

Phase 3

Completed

Conditions: Breast Cancer

First Posted Date: 2004-04-14

Last Posted Date: 2020-04-01

Lead Sponsor: NCIC Clinical Trials Group

Target Recruit Count: 224

Registration Number: NCT00003032

Locations: 🇨🇦
Humber River Regional Hospital, Weston, Ontario, Canada
🇨🇦
Centre Hospitalier Universitaire de Quebec, Pavillion de Quebec, Quebec City, Quebec, Canada
🇨🇦
William Osler Health Centre, Brampton, Ontario, Canada

and more 22 locations